Universal marker and detection tool for human sarcoma circulating tumor cells

Cancer Research

Volumn 74, Issue 6, 2014, Pages 1645-1650

  Satelli, Arun ^a   Mitra, Abhisek ^a   Cutrera, Jeffry J ^a   Devarie, Marcos ^a   Xia, Xueqing ^a   Ingram, Davis R ^b   Dibra, Denada ^b   Somaiah, Neeta ^c   Torres, Keila E ^b   Ravi, Vinod ^c   Ludwig, Joseph A ^c   Kleinerman, Eugenie S ^a   Li, Shulin ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b Departments of Surgical Oncology and Cancer Biology   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE PROTEIN; CELL SURFACE VIMENTIN; K RAS PROTEIN; PROTEIN MDM2; PROTEIN P53; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 3; VIMENTIN;

ARTICLE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RECURRENCE; CELL SURFACE DISPLAY; CIRCULATING TUMOR CELL; CONTROLLED STUDY; DISEASE ASSOCIATION; FLOW CYTOMETRY; FLT4 GENE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN CELL; KRAS GENE; MDM 2 GENE; METASTASIS; MUTATIONAL ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; SARCOMA; SENSITIVITY AND SPECIFICITY; SINGLE CELL ANALYSIS; TP53 GENE;

ANTIBODIES, MONOCLONAL; BASE SEQUENCE; CELL LINE, TUMOR; DNA MUTATIONAL ANALYSIS; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GENE AMPLIFICATION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICROSCOPY, FLUORESCENCE; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; SARCOMA; SENSITIVITY AND SPECIFICITY; SINGLE-CELL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; VIMENTIN;

EID: 84896498173     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-1739     Document Type: Article

References (14)

1. Mackall CL, Meltzer PS, Helman LJ. Focus on sarcomas. Cancer Cell 2002;2:175-8. (Pubitemid 41043972)
2. Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer 2004;4:448-56. (Pubitemid 38745530)
3. Parkinson DR, Dracopoli N, Petty BG, Compton C, Cristofanilli M, Deisseroth A, et al. Considerations in the development of circulating tumor cell technology for clinical use. J Transl Med 2012;10:138.
4. Sieuwerts AM, Kraan J, Bolt J, van der Spoel P, Elstrodt F, Schutte M, et al. Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst 2009;101:61-6.
5. Balic M, Williams A, Lin H, Datar R, Cote RJ. Circulating tumor cells: from bench to bedside. Annu Rev Med 2013;64:31-44.
6. Satelli A, Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci 2011;68:3033-46.
7. Powell AA, Talasaz AH, Zhang H, Coram MA, Reddy A, Deng G, et al. Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS ONE 2012;7: e33788.
8. Cutrera J, Dibra D,Xia X,HasanA,Reed S, Li S, et al. Discovery of a linear peptide for improving tumor targeting of gene products and treatment of distal tumors by IL-12 gene therapy. Mol Ther. 2011;19:1468-77.
9. Huet D, Bagot M, Loyaux D, Capdevielle J, Conraux L, Ferrara P, et al. SC5 mAb represents a unique tool for the detection of extracellular vimentin as a specific marker of Sezary cells. J Immunol 2006;176: 652-9. (Pubitemid 43023314)
10. Steinmetz NF, Cho CF, Ablack A, Lewis JD, Manchester M. Cowpea mosaic virus nanoparticles target surface vimentin on cancer cells. Nanomedicine 2011;6:351-64.
11. Zietz C, Rossle M, Haas C, Sendelhofert A, Hirschmann A, Sturzl M, et al. MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas. Am J Pathol 1998;153: 1425-33. (Pubitemid 28509898)
12. Ladanyi M, Cha C, Lewis R, Jhanwar SC, Huvos AG, Healey JH, et al. MDM2 gene amplification in metastatic osteosarcoma. Cancer Res 1993;53:16-8. (Pubitemid 23019370)
13. Yokoyama R, Schneider-Stock R, Radig K, Wex T, Roessner A. Clinicopathologic implications of MDM2, p53 and K-ras gene alterations in osteosarcomas: MDM2 amplification and p53 mutations found in progressive tumors. Pathol Res Pract 1998;194: 615-21. (Pubitemid 28451457)
14. Dubois SG, Epling CL, Teague J, Matthay KK, Sinclair E. Flow cytometric detection of Ewing sarcoma cells in peripheral blood and bone marrow. Pediatr Blood Cancer 2010;54:13-8.